firstwordpharmaApril 04, 2019
Tag: DBV Technologies , Shares , offering
DBV Technologies (the "Company") (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its intention to issue and sell, subject to market conditions, in a global offering of new ordinary shares, which may be in the form of American Depositary Shares (ADSs), up to 5,217,392 new ordinary shares, the subscription of which is reserved to specified categories of investors. The global offering will be comprised of an offering of ADSs in the United States, Canada and certain other countries outside of Europe and a private placement of ordinary shares in Europe (including France). In addition, the Company intends to grant the underwriters a 30-day option to purchase additional ordinary shares, which may be in the form of ADSs, in an aggregate amount of up to 782,608 ordinary shares (including in the form of ADSs) proposed to be sold in the global offering, on the same terms and conditions. Each ADS offered represents the right to receive one-half of one ordinary share. The ADSs are listed on the Nasdaq Global Select Market under the symbol "DBVT", and the Company's ordinary shares are listed on Euronext Paris under the symbol "DBV".
Goldman Sachs & Co. LLC and Citigroup are acting as joint lead book-running managers for the global offering. H.C. Wainwright & Co. is acting as lead manager for the global offering (together, the "Underwriters").
The price in euros at which ordinary shares will be sold and the price in dollars at which ADSs will be sold in the global offering, as well as the final number of ordinary shares (including in the form of ADSs), will be determined following a bookbuilding process commencing immediately and will not be less than (i) the volume weighted-average of the trading price of the Company's ordinary shares on Euronext Paris on the trading day prior to pricing of the global offering or (ii) the average of the trading prices of the Company's ordinary shares on Euronext Paris over five (5) consecutive trading days chosen from among the thirty (30) trading days prior to pricing of the global offering, subject to a maximum discount, in each case, of 15%. The new ordinary shares will be issued through a capital increase without shareholders' pre-emptive rights reserved to a category of persons under the provisions of Article L. 225-138 of the French Commercial Code and pursuant to the decision of the Company's Board of Directors (Conseil d'Administration) on April 3, 2019, in accordance with the delegations granted pursuant to the Resolutions 25, 26 and 28 adopted at the ordinary and extraordinary meeting of the Company's shareholders (Assemblée Générale Mixte) held on June 22, 2018. The global offering will be open only to persons who are natural persons or legal entities, including companies, trusts, investment funds or other investment vehicles whatever their form, governed by either French or foreign law, that invest on a regular basis in the pharmaceutical, biotechnological or medical technology sector; and/or companies, institutions or entities whatever their form, French or foreign, that carry out a significant part of their activity in these sectors. In order to purchase ordinary shares and/or ADSs, potential investors will be required to execute and provide to the Underwriters an investor letter representing that they satisfy the foregoing investor criteria.
The final number of ordinary shares offered, including the number of ordinary shares offered in the form of ADSs, and the subscription price therefor will be decided by the Company's Chief Executive Officer (Directeur Général), in accordance with a sub-delegation granted by the Company's Board of Directors (Conseil d'Administration) on April 3, 2019, further to the favorable opinion of Mr. Michel de Rosen, independent director and Chairman of the Board of Directors; provided, that in no event shall the Company be permitted to issue more than 20% of its share capital outstanding prior to commencement of the global offering.
The global offering will commence immediately and the Company plans to announce the result of the global offering as soon as practicable after pricing thereof in a subsequent press release. The Company plans to use the net proceeds from the global offering, together with its existing cash and cash equivalents, to fund the development and, if approved, prepare for the commercialization of Viaskin Peanut, to advance development of the Company's other product candidates and for working capital and general corporate purposes.
Entities affiliated with Baker Bros. Advisors LP and Bpifrance Participations S.A., which are existing shareholders, have indicated an interest in purchasing, in the aggregate, at least 25.0% of the ordinary shares (including in the form of ADSs) in this offering at the public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no ordinary shares and/or ADSs in this offering to these entities, or these entities may determine to purchase more, fewer or no ordinary shares and/or ADSs in this offering.
The representatives of Baker Bros. Advisors LP and Bpifrance Participations S.A. to the Company's Board of Directors (Conseil d'Administration) did not take part in the vote on the resolutions (relating to the approval for the launch of the global offering and for the delegation of authority) at the meeting of the Board of Directors (Conseil d'Administration) held on April 3, 2019.
A registration statement on Form F-3, as amended, relating to the securities to be issued in the global offering was filed with the Securities and Exchange Commission and initially became automatically effective on July 27, 2016. The offering of ordinary shares in the form of ADSs will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the Securities and Exchange Commission and will be available on the Securities and Exchange Commission's website at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying prospectus may also be obtained for free from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: 1-866-471-2526, facsimile: 212-902-9316 or via email: prospectusgroup-ny@ny.email.gs.com; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York, 11717 or via telephone: 800-831-9146. No prospectus subject to approval by the French Autorité des Marchés Financiers (AMF) has been filed in France in connection with the global offering.
Register as Visitor to CPhI China 2019!
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: